CrownBio expands immuno-oncology offerings

By Melissa Fassbender

- Last updated on GMT

The additions come in response to a growing demand for immuno-oncology services (Image: iStock/royaltystockphoto)
The additions come in response to a growing demand for immuno-oncology services (Image: iStock/royaltystockphoto)

Related tags Flow cytometry Medicine

Crown Bioscience has expanded its immuno-oncology platform at its facilities in Europe, the US, and Asia to include immunophenotyping analysis.

The expanded offerings include a collection of validated models and services for in vivo pharmacodynamic and efficacy studies, including multi-color flow cytometry, immunohistochemistry, and multiplex ELISA.

According to Jean Pierre Wery, President of Crown Bioscience, the additions come in response to a growing demand for immuno-oncology services - a market which is expected to see annual revenues of $25bn to $40bn by 2020, according to a report by Tufts​.

In particular, single cell-based FACS analysis has become a standard and essential tool to investigate the impact of Immuno-Oncology therapy in both murine and humanized systems in the preclinical setting​,” said Henry Li, VP of Translational Oncology at Crown Bioscience.

The ability to gate different sub-populations of T lymphocytes and myeloid compartment provides a rapid way for our clients to understand the impact of both single and combination therapies to significantly extend the reach of potential therapeutic effect across a larger population of patients​.”.

The company’s collection of syngeneic models, as well as its MiXeno™, MuPrime™, HuGEMM™ and humanized PDX platforms, can all be profiled using the immunophenotyping capacities for both pretreatment baseline and post treatment pharmacodynamic readouts.

The announcement follows CrownBio’s launch of its high throughput-screening platform, HuScreen in May. As Outsourcing-Pharma.com previously reported​, the platform seeks to improve preclinical studies using patient-derived xenograft (PDX) models.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us

Products

View more

Webinars